Introduction
============

Colorectal cancer (CRC) remains a major cause of cancer-related morbidity and mortality in the world. 5-Fu based adjuvant chemotherapy after curative surgery is considered as standard therapy for stage II/III CRC. Unfortunately, approximately 40% of stage these patients develop local recurrence or metastatic disease which mainly due to chemoresistance [@B1]. To date, the mechanisms of chemoresistance in CRC have not been fully elucidated.

Notch signaling pathway plays an essential role in promoting cell survival [@B2], [@B3]. Activation of Notch pathway leads to the release of the Notch intracellular domain (NICD), which translocates to the nucleus and activates transcription of numerous downstream target genes, including HES1 [@B4], [@B5]. Aberrant activation of Notch signaling pathway is involved in chemoresistance in multiple cancers including CRC, and blocking Notch signaling pathway by a γ-secretase inhibitor could enhance chemosensitivity [@B6]-[@B9].

As a downstream target of canonical Notch signaling pathway, HES1 plays a vital role in chemoresistance. In ovarian cancer, inhibiting the Notch pathway by γ-secretase inhibitor could decrease expression of HES1 mRNA and sensitize cells to paclitaxel [@B6]. HES1 might modulate the therapeutic resistance by mediating Gli1 expression in medulloblastoma and glioblastoma [@B10]. However, except for Notch signaling pathway, HES1 signaling could be activated by other pathways, including Hedgehog, c-Jun N terminal kinase and TGF-a/Ras/MAPK pathways, which are also involved in chemoresistance [@B11]-[@B13]. In addition, HES1 acts as a marker of colon cancer stem cells (CSCs), which might also contribute to tumor recurrence after 5-Fu based adjuvant chemotherapy [@B14]-[@B16]. Thus, the role of HES1 in CRC chemoresistance is unpredictable upon Notch signaling pathway pathway status.

In this study, we investigated the clinical significance of chemo-response of HES1 in stage II/III CRC patients (n=121) using tissue microarray. Chemosensitivity was examined in colorectal cancer cells with over-expression and inhibition of HES1. Furthermore, the enriched pathways and different expression of genes in cells which over-expressed HES1 were investigated by gene expression microarray. Expression changes of the main genes related to chemoresistance were confirmed by qPCR and western blot analysis.

Methods
=======

Patients and tissues
--------------------

This retrospective study included 121 staged II/III CRC patients who underwent radical resection (R0) and received 5-Fu based adjuvant chemotherapy. Overall survival (OS) period was defined as the period between diagnosis and death or the last follow-up. Disease free survival (DFS) was defined as the period between diagnosis and the first clinical or pathologic evidence of local or distant recurrent disease. Written informed consent was obtained from each patient before surgery. The study was approved by the Institutional Review Board of Sun Yat-Sen University.

Immunohistochemistry analysis
-----------------------------

Immunohistochemistry analysis was carried out according to the Envision System (Dako Cytomation, Glostrup, Denmark) guidance. In brief, each TMA slides was deparaffinzed and rehydrated through graded ethanol. Sodium citrate was used for antigen retrieval. Slides underwent 0.3% hydrogen peroxide solution to block endogenous peroxidase activity. Then samples was incubated with the primary antibody anti-HES1 (1:400; Abcam, ab71559), at 4°C overnight. After incubation with secondary (goat) antibody, slides were developed in diaminobenzine (EnVision, DAKO) and counterstained with haematoxylin.

Cell culture and lentivirus infection
-------------------------------------

RKO, HCT8 and LOVO were obtained from Chinese Academy of Science Cell Bank (Shanghai, China). All cell lines were cultured in RPMI-1640 or DMEM-F12 medium (Gibco, China) with 10% FBS (Gibco, China), 100U/mL penicillin and 100ug/mL streptomycin (Gibco, China) at 37°C with 5% CO~2~. Lentiviral plasmid for over-expressing HES1 and plasmid for negative control (disrupted DNA-binding domain) were purchased from Addgene (No.17624 and No.24982). The plasmids were verified via sequencing. ShRNA lentivirus was constructed by GENECHEM CO. (Shanghai, China). GV248 backbone was used, with the shRNA sequences: SCR (scramble): 5\'-TTCTCCGAACGTGTCACGT-3\'; shRNA-1: 5\'-AGATCAAT GCCATGACCTA-3\'; shRNA-2: 5\'- GGACATTCTGGAAATGACA -3\'. In brief, the lentiviruses were produced by transfecting 293FT cells with pGC-LV, pPAX2 and pMD2.G plasmids mix and lipofectamine-2000 (Invitrogen, NY) in Opti-MEM medium (Gibco, USA). Virus was collected and stored at -80°C before using, and titrated with Lenti-X qRT-PCR Titration Kit (Clontech, CA). Cell lines were infected at a MOI (Multiplicity of Infection) of 10 with 8ug/mL polybrene (Millipore, MA). Knockdown efficiency higher than 80% was considered acceptable. For the following experiments, the positive cells population was enriched using puromycin selection or FACS sorting for GFP.

Cell viability assay
--------------------

Cells were seeded 2000 per well in 96-well plates for 24 hours, then treated with 5-Fu at various concentrations (0, 0.5, 1, 5, 10, 50μmol/L). Sixty hours later, 10μl of CCK-8 solution (Cell counting kit-8, *Sigma*, St. Louis, MO, *USA*) was added to each well. Absorbance was determined at 450 nm after 3 hours of incubation. Cell viability was calculated as following: Viability = (OD test group-OD blank group) / (OD control group-OD blank group) × 100 %, and IC50 (half maximal inhibitory concentration) was calculated from the dose-response curves. All experiments were repeated in triplicate.

Gene expressional profiles and analysis
---------------------------------------

RNAs were extracted from RKO-HES1 and RKO-Mutant cells. RNA integrity was assessed by standard denaturing agarose gel electrophoresis. The Human 12x135K Gene Expression Array was manufactured by Roche NimbleGen. 45,033 genes are collected from the authoritative data source including National Center of Biotechnology Information (NCBI). Double-strand cDNA (ds-cDNA) was synthesized from total RNA, which was then cleaned and labeled before hybridization. Differentially expressed genes were identified through Fold change filtering. Genes with fold-change≥2.0 expression were enrolled. Realtime RT-PCR was used to confirm the results.

Pathways enrichment analysis was based on KEGG (Kyoto Encyclopedia of Genes and Genomes) database, which identified the biological pathways that had a significant enrichment of differently expressed genes. The *P*-values denote the significance of the pathways, with cut-off at 0.05.

Immunofluorescence and western blot analysis
--------------------------------------------

For immunofluorescence assay, cells were grown on glass slices and fixed in 4 % formaldehyde for 10 min, permeabilized through 0.3 % Triton X-100. Then the slices were blocked in goat serum for 15 min, 37°C and incubated overnight at 4°C with anti-E-cadherin (1:80, Bioworld, MN, USA), anti-N-cadherin (1:80, Bioworld, MN, USA). Samples were washed three times before incubated with goat TRITC labeled secondary antibody (1:70, Bioworld, MN, USA) at 37°C for 1 h. DAPI (Genview Inc, Shanghai, China) was used for counterstaining. Fluorescence was visualized with a microscope under ×400 magnification.

Total protein was extracted using RIPA Lysis Buffer (Beyotime, China) and PMSF (Sigma-Aldrich). The proteins were transferred to NC membranes (Millipore Corp, MA USA) using the TransBlot System (Bio-Rad, CA, USA). The membranes were blocked in 5% w/v non-fat milk in TBS and incubations were performed overnight at 4°C. The membranes were then washed using TBST and incubated with secondary antibodies (1:10000, IRDye Goat IgG, LI-COR Bioscience, NE USA) for 1h at room temperature. Protein staining was detected using the Odyssey Imaging System (LI-COR Biosciences, NE USA). The following primary antibodies were used: GAPDH (1:10000, Proteintech Group, Chicago USA), ABCC1 (1:100, Abcam, ab24102), ABCC2 (1:100, Abcam, ab3373), P-gp1 (1:2000, Abcam, ab129450).

Statistics
----------

An open source software TMAJ (Johns Hopkins, Baltimore, USA) was applied to measure the HES1 expression index as described elsewhere [@B17]. The median of HES1 expression was employed for the cut-point.

Statistical analysis was carried out using SPSS 17.0 (*SPSS*, *Chicago*, IL, *USA*). Correlations between clinicopathologic data and HES1 expression were analyzed using Chi-square test or Fisher\'s exact test. Kaplan-Meier survival curves were preformed to estimate OS and DFS. A value of P\<0.05 was considered statistically significant.

Results
=======

Correlation between HES1 level and clinicopathological variables
----------------------------------------------------------------

To study the clinical significance of HES1 expression, 121 CRC samples in stage II/III (n=121) patients who received 5-Fu based adjuvant chemotherapy were examined by tissue microarray. HES1 protein was mainly located in cancer cell cytoplasm (Fig.[1](#F1){ref-type="fig"}A). Patients were divided into high and low HES1 expression groups, using the median expression index (2.95) as the cutpoint. Clinic-pathological characteristics and correlation with HES1 expression were shown in Table [1](#T1){ref-type="table"}. Correlation analysis revealed that HES1 expression was significantly correlated with CEA level (*P*=0.038), not with age, gender, CA199 level, tumor type, location, stage or recurrence. For stage II patients only, HES1 expression was correlated with CA199 level (*P*=0.016) and recurrence rate (*P*=0.022) (Table [2](#T2){ref-type="table"}).

Kaplan-Meier analysis revealed that stage II patients with higher HES1 expression level had poor OS (*P*=0.015) and DFS (*P*=0.042) (Fig. [1](#F1){ref-type="fig"}B).

Over-expression of HES1 induce chemoresistance in CRC cells
-----------------------------------------------------------

Chemoresistance is a key obstacle to the efficacy of CRC treatment and may result in recurrence. To determine the potential role of HES1 in chemoresistance, stable over-expression and inhibition of HES1 gene were established in colon cancer cell lines including RKO, HCT8 and LOVO, which were then exposed to different concentrations of 5-Fu treatment *in vitro*. CCK8 test showed that HES1 over-expression significantly promoted cell viability of RKO and HCT8 cells, whereas HES1 inhibition significantly decreased cell viability of LOVO cells (Fig.[1](#F1){ref-type="fig"}C). The IC50 of RKO (*P*=0.016 vs vehicle, *P*=0.001 vs control) and HCT8 cells (*P*\<0.001 vs vehicle, *P*\<0.001 vs control) were significantly increased by HES1 over-expression. However, HES1 inhibition resulted in a significant decreased IC50 in LOVO cells (*P*\<0.001 vs vehicle, *P*\<0.001 vs control) (Fig.[1](#F1){ref-type="fig"}D).

Over-expression of HES1 induce EMT in CRC cells
-----------------------------------------------

To determine the mechanisms of HES1 mediated CRC chemoresistance, RKO cell lines that stable over-expressed wild type HES1 and mutant HES1 gene were stablished. Changes in two cell lines were determined by whole-genome cDNA microarray. As shown in Fig.[2](#F2){ref-type="fig"}A, several pathways were changed by HES1 over-expression. Briefly, pathways with drug metabolism were up-regulated, and pathways with adhering junction, focal adhesion and actin cytoskeleton were markedly down-regulated. 2668 genes were up-regulated after HES1 over-expression, while 1304 genes were down-regulated. Genes with most significant changes were shown in Table [3](#T3){ref-type="table"}.

Considering the changes in adhesion and actin cytoskeleton pathways, we hypothesized HES1 over-expression might induce EMT. To verify this idea, we examined the expression of two critical EMT markers, E-cadherin and N-cadherin, in RKO and LOVO cell lines. Immunofluorescence assay revealed that HES1 over-expression increased the level of N-cadherin, and decreased E-cadherin in RKO cells. The opposite results were found in LOVO cells after HES1 inhibition (Fig.[2](#F2){ref-type="fig"}B). Thus, HES1 over-expression might induce EMT in CRC cells.

Over-expression of HES1 induce ABC transporter genes in CRC cells
-----------------------------------------------------------------

Since several members of ATP-binding cassette transporter family (ABC) are up-regulated by HES1 over-expression in cDNA microarray, we reasoned that ABC transporter proteins could be more commonly induced by HES1, and rendered chemoresistance. To test this hypothesis, we examined expression of ABCC1, ABCC2 and P-gp1 (three critical molecules in drug metabolism) in CRC cell lines mentioned above. QPCR and western-blot analysis showed that HES1 over-expression increased ABCC1, ABCC2 and P-gp1 expression in RKO and HCT8 cells, and HES1 inhibition of in LOVO cells showed opposite results (Fig.[2](#F2){ref-type="fig"}C, 2D). Thus, these data suggested that HES1 might prompt chemoresistance by inducing ABC transporter proteins in CRC cells.

Discussion
==========

Previous studies have revealed that Notch signaling pathway involved in CRC chemoresistance. However, as an important downstream transcriptional factor in Notch signaling pathway, the role of HES1 in CRC chemoresistance is still unclear. In this study, we investigated the clinical significance of HES1 expression in stage II/III CRC patients who received adjuvant chemotherapy, and demonstrated its role of chemoresistance *in vitro*.

Notch signaling pathway plays important role in the differentiation balance of intestinal crypts and carcinogenesis in CRC. Several studies showed HES1 is over-expressed in colorectal cancer *[@B8], [@B18], [@B19], and its* prognostic value in CRC has also been investigated [@B18], [@B20]. However, *there is no study showed its role in CRC chemotherapy. In this study, we found* stage II CRC patients with high HES1 expression had higher recurrence rate and poor prognosis (OS and DFS) *after 5-Fu based adjuvant chemotherapy*. This might be the result from the chemoresistance induced by HES1 over-expression. This correlation was not found in stage III patients. To our knowledge, this is the first time establishing a correlation between HES1 expression and CRC recurrence after *5-Fu based adjuvant chemotherapy.*

*Notch signaling was found to participate in chemoresistance in* numerous cancers and inhibiting the Notch pathway could enhance chemosensitivity [@B9], [@B21]-[@B23]. *Whether HES1 is involved in colorectal chemoresistance is unclear. What is more,* HES1 could be activated by other upstream pathways besides Notch pathways [@B11]-[@B13], *and HES1 is considered as* a marker of colon CSCs which also might contribute to chemoresistance [@B16]. Thus, the role of HES1 in CRC chemoresistance is unpredictable. In this study, we found HES1 could promote chemoresistance of CRC and targeted inhibited HES1 could enhance chemosensitivity *in vitro*.

Epithelial-mesenchymal transition (EMT) has been shown to play a crucial role in chemoresistance and tumor recurrence [@B24]-[@B26]. Increasing evidences suggest EMT-associated transcription factors are involved in chemoresistance in different cancers [@B27]-[@B29]. In colorectal cancer, EMT could prompt chemoresistance to oxaliplatin by upregulating P-gp expression [@B30]. Notch signaling could promote chemoresistance via EMT in other type of cancer [@B31], [@B32]. In the present study, cDNA microarray profiling and western blot analysis demonstrated that over-expression of HES1 could down-regulate E-cadherin and up-regulate N-cadherin. Thus, HES1 might prompt chemoresistance by the induction of EMT.

ATP-binding cassette transporter (*ABC*) transporters involved in *chemoresistance by* decreasing cellular drug uptake and accumulation, and are considered as a major cause for chemotherapy failure. Over-expression of the ABCC1 transporter confers resistance to a wide range of anticancer drugs [@B33], [@B34]. In breast cancer, ABCC3 transporter is confirmed involving in drug resistance to chemotherapy [@B35]. The transfection of human embryonic kidney cells with the ABCC10 gene conferred resistance to various anticancer drugs including paclitaxel, docetaxel, vincristine, gemcitabine [@B36]-[@B39]. In this study, we found expression of several members of ABC transporters was increased after HES1 over-expression by cDNA microarray profiling, and western blot confirmed P-gp1, ABCC1 and ABCC2 are up-regulated by over-expression of HES1. Therefore, up-regulation of *ABC* transporters might be one of the mechanisms of HES1 induced chemoresistance.

In conclusion, our study showed that HES1 was an unfavorable factor for recurrence in stage II CRC patients who received adjuvant chemotherapy, and HES1 could promote CRC chemoresistance via induction of EMT and ABC transporters. Thus, HES1 might be a novel therapeutic strategy in CRC treatment.
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![**HES1 prompted chemoresistance in CRC** (A) Representative images of HES1 staining in normal colorectal tissues and CRC (Magnification: ×200). (B) Kaplan-Meier survival curves for over-all survival (left) and disease-free survival (right) of stage II CRC patients who received 5-Fu based adjuvant chemotherapy. (C) Cell viability of RKO, HCT8, LOVO in different 5-Fu concentrations. (D) IC50 of RKO, HCT8, LOVO in different 5-Fu concentrations. The bars represent means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](jcav08p2802g001){#F1}

![**HES1 induced EMT and ABC transporters proteins of CRC cells** (A) cDNA microarray of HES1 over-expression in RKO. Pathway enrichment analysis on the distinguished expressed genes. Enrichment score values are shown as-log10 (*P* value). (B) Immunofluorescence staining for E-cadherin and N-cadherin in RKO and LOVO. (C) qPCR assay of ABCC1, ABCC2 and P-gp1 in RKO, HCT8 and LOVO. Western blot analysis of ABCC1, ABCC2 and P-gp1 in RKO, HCT8 and LOVO. The bars represent means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](jcav08p2802g002){#F2}

###### 

Correlation between expression of HES1 and clinicopathological variables

  Variables                      All cases   HES1 expression   *P* value^†^   
  ------------------------------ ----------- ----------------- -------------- ---------
  No. of patients                121         60                61             \-
  Median HES1 expression index   2.95        0.53              9.70           \-
  Age                                                                         
  \<60/≥60                       67/54       37/23             30/31          0.167
  Gender                                                                      
  Male/Female                    76/45       40/20             36/25          0.384
  CEA, ng/ml                                                                  
  \<5/≥5                         74/41       32/26             42/15          0.038\*
  CA199, U/ml                                                                 
  \<37.5/≥37.5                   79/31       39/17             40/14          0.606
  Stage                                                                       
  II/III                         58/63       25/35             33/28          0.171
  Histological type                                                           
  Adenocarcinoma/Mucinous        106/14      55/5              51/9           0.255
  Location                                                                    
  Colon/Rectum                   51/69       26/34             25/35          0.853
  Recurrence                                                                  
  Yes/No                         28/93       10/50             18/43          0.094

^†^The *P* value was calculated by Chi square test.

\* *P*\<0.05.

###### 

Correlation between expression of HES1 and clinicopathological variables in stage II patients

  Variables                 All cases   HES1 expression   *P* value^†^   
  ------------------------- ----------- ----------------- -------------- ----------
  No. of patients           58          25                33             \-
  Age                                                                    
  \<60/≥60                  26/32       13/12             13/20          0.339
  Gender                                                                 
  Male/Female               36/22       15/10             21/12          0.777
  CEA, ng/ml                                                             
  \<5/≥5                    35/20       13/9              22/11          0.199
  CA199, U/ml                                                            
  \<37.5/≥37.5              38/15       17/7              21/8           0.016\*
  Histological type                                                      
  Adenocarcinoma/Mucinous   51/7        23/2              28/5           0.687^‡^
  T stage                                                                
  T3/T4                     54/4        25/0              29/4           0.126^‡^
  Location                                                               
  Colon/Rectum              20/38       8/17              12/21          0.729
  Recurrence                                                             
  Yes/No                    13/45       2/23              11/22          0.022\*

^†^The *P* value was calculated by Chi square test^.^

^‡^The *P* value was calculated by Fisher\'s exact test.

\* *P*\<0.05.

###### 

Genes with most significant expression changes by overexpression HES1 in cDNA microarray

  NCBI Gene ID   Gene name   Fold change^†^   Description
  -------------- ----------- ---------------- ----------------------------------------------------
  NM 3598        IL13RA2     7.34±0.47        Interleukin 13 receptor, alpha 2
  NM 4582        MUC1        6.71±1.02        Mucin 1, cell surface associated
  NM1396         CRIP1       5.25±0.73        Cysteine-rich protein 1 (intestinal)
  NM 1000        CDH2        5.19±0.24        Cadherin 2, type 1, N-cadherin
  NM19900        ABCC1       4.62±0.13        ATP-binding cassette, sub-family C, member 1
  AF541977       ABCC4       3.98±0.44        ATP-binding cassette, sub-family C, member 4
  NM1606         ABCA2       3.62±0.81        ATP-binding cassette, sub-family A, member 2
  NM33           ABCD1       3.25±0.63        ATP-binding cassette, sub-family D (ALD), member 1
  NM6624         FSCN1       -17.31±2.99      Fascin homolog 1, actin-bundling protein
  NM26012        NELF        -14.45±0.68      Nasal embryonic LHRH factor
  NM5829         PXN         -12.88±1.98      Paxillin
  NM 4134        MAP4        -8.24±1.67       Microtubule-associated protein 4

^†^ Data represent as means ± SEM for duplicate samples.
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